These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 20562737

  • 1. Effect of sirolimus on calcineurin inhibitor-induced nephrotoxicity using renal expression of KLOTHO, an antiaging gene.
    Han DH, Piao SG, Song JH, Ghee JY, Hwang HS, Choi BS, Kim J, Yang CW.
    Transplantation; 2010 Jul 27; 90(2):135-41. PubMed ID: 20562737
    [Abstract] [Full Text] [Related]

  • 2. Different renal toxicity profiles in the association of cyclosporine and tacrolimus with sirolimus in rats.
    Lloberas N, Torras J, Alperovich G, Cruzado JM, Giménez-Bonafé P, Herrero-Fresneda I, Franquesa Ml, Rama I, Grinyó JM.
    Nephrol Dial Transplant; 2008 Oct 27; 23(10):3111-9. PubMed ID: 18469305
    [Abstract] [Full Text] [Related]

  • 3. Different profile of gene expression of cytokines in peripheral blood mononuclear cells of transplant recipients treated with m-TOR inhibitor and calcineurin inhibitor.
    Niemczyk M, Zegarska J, Pawłowska M, Wyzgał J, Ciszek M, Paczek L.
    Transpl Immunol; 2009 Jan 27; 20(3):139-42. PubMed ID: 18834941
    [Abstract] [Full Text] [Related]

  • 4. Correlation between cyclosporine-induced nephrotoxicity in reduced nephron mass and expression of kidney injury molecule-1 and aquaporin-2 gene.
    Hong ME, Hong JC, Stepkowski S, Kahan BD.
    Transplant Proc; 2005 Dec 27; 37(10):4254-8. PubMed ID: 16387092
    [Abstract] [Full Text] [Related]

  • 5. Drug interaction between cyclosporine and mTOR inhibitors in experimental model of chronic cyclosporine nephrotoxicity and pancreatic islet dysfunction.
    Piao SG, Bae SK, Lim SW, Song JH, Chung BH, Choi BS, Yang CW.
    Transplantation; 2012 Feb 27; 93(4):383-9. PubMed ID: 22267156
    [Abstract] [Full Text] [Related]

  • 6. Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients.
    Raichlin E, Khalpey Z, Kremers W, Frantz RP, Rodeheffer RJ, Clavell AL, Edwards BS, Kushwaha SS.
    Transplantation; 2007 Aug 27; 84(4):467-74. PubMed ID: 17713429
    [Abstract] [Full Text] [Related]

  • 7. Influence of N-acetylcysteine on Klotho expression and its signaling pathway in experimental model of chronic cyclosporine nephropathy in mice.
    Piao SG, Kang SH, Lim SW, Chung BH, Doh KC, Heo SB, Jin L, Li C, Yang CW.
    Transplantation; 2013 Jul 27; 96(2):146-53. PubMed ID: 23765110
    [Abstract] [Full Text] [Related]

  • 8. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 9. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 10. Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat.
    Wittmann S, Daniel C, Stief A, Vogelbacher R, Amann K, Hugo C.
    Transplantation; 2009 May 15; 87(9):1290-9. PubMed ID: 19424027
    [Abstract] [Full Text] [Related]

  • 11. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation.
    Stephany BR, Augustine JJ, Krishnamurthi V, Goldfarb DA, Flechner SM, Braun WE, Hricik DE, Dennis VW, Poggio ED.
    Transplantation; 2006 Aug 15; 82(3):368-74. PubMed ID: 16906035
    [Abstract] [Full Text] [Related]

  • 12. Sirolimus increases transforming growth factor-beta1 expression and potentiates chronic cyclosporine nephrotoxicity.
    Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF.
    Kidney Int; 2004 Apr 15; 65(4):1262-71. PubMed ID: 15086465
    [Abstract] [Full Text] [Related]

  • 13. TGF-β1 mediates sirolimus and cyclosporine A-induced alteration of barrier function in renal epithelial cells via a noncanonical ERK1/2 signaling pathway.
    Martin-Martin N, Slattery C, McMorrow T, Ryan MP.
    Am J Physiol Renal Physiol; 2011 Dec 15; 301(6):F1281-92. PubMed ID: 21880834
    [Abstract] [Full Text] [Related]

  • 14. Rapamycin and cyclosporine have different effects on expression of Ang-1 and Ang-2 and Tie2 in rat renal allograft with chronic allograft nephropathy.
    Ma X, Lu YP, Yang L, Song J, Luo GH, Shi YJ, Li YP.
    Transplant Proc; 2008 Oct 15; 40(8):2804-7. PubMed ID: 18929866
    [Abstract] [Full Text] [Related]

  • 15. Is sirolimus responsible for proteinuria?
    Dervaux T, Caillard S, Meyer C, Ellero B, Woehl-Jaegle ML, Hannedouche T, Wolf P, Moulin B.
    Transplant Proc; 2005 Oct 15; 37(6):2828-9. PubMed ID: 16182822
    [Abstract] [Full Text] [Related]

  • 16. Hypertension induced by immunosuppressive drugs: a comparative analysis between sirolimus and cyclosporine.
    Reis F, Parada B, Teixeira de Lemos E, Garrido P, Dias A, Piloto N, Baptista S, Sereno J, Eufrásio P, Costa E, Rocha-Pereira P, Santos-Silva A, Figueiredo A, Mota A, Teixeira F.
    Transplant Proc; 2009 Apr 15; 41(3):868-73. PubMed ID: 19376375
    [Abstract] [Full Text] [Related]

  • 17. Affects of immunosuppression on circulating dendritic cells: an adjunct to therapeutic drug monitoring after heart transplantation.
    Barten MJ, Garbade J, Bittner HB, Fiedler M, Dhein S, Thiery J, Mohr FW, Gummert JF.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):2011-7. PubMed ID: 17161355
    [Abstract] [Full Text] [Related]

  • 18. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov 20; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 19. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus.
    Teutonico A, Schena PF, Di Paolo S.
    J Am Soc Nephrol; 2005 Oct 20; 16(10):3128-35. PubMed ID: 16107580
    [Abstract] [Full Text] [Related]

  • 20. Angiotensin II blockade upregulates the expression of Klotho, the anti-ageing gene, in an experimental model of chronic cyclosporine nephropathy.
    Yoon HE, Ghee JY, Piao S, Song JH, Han DH, Kim S, Ohashi N, Kobori H, Kuro-o M, Yang CW.
    Nephrol Dial Transplant; 2011 Mar 20; 26(3):800-13. PubMed ID: 20813770
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.